SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 21 Publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 Mof2SpVv[3Srb36gRZN{[Xl? MVSyOUDPxE1? MUGzNEBucW5? MmHtSG1UV8Li MkTYZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG= M3vo[VI3OjJ|MkWx
MDA-MB-231 NYnxNFJWTnWwY4Tpc44hSXO|YYm= M3TTfVIh|ryP NFfVfngzPCCq MV\s[ZN{\W6nczDDR2wzKGmwZIXjeIlwdiCkeTDUUmbPuQ>? MV6yOlExODh2OB?=
rBMSCs MoPvSpVv[3Srb36gRZN{[Xl? MXmxNEDPxE1? MWKyMlUhcA>? NUPZUJUy\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN|g> NX3T[mNqOjZyNUOyOlY>
MG63 NX3pUVdyTnWwY4Tpc44hSXO|YYm= MYSxNE8zOC9|MDFOwG0> NGLTTZMzPCCq NYT4fJA2e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKHCqb4PwbI9zgWyjdHXkJJA{QCCrbnT1Z4VlKGK7IFPkR4wzKGmwIHGgZ49v[2WwdILheIlwdiBvZHXw[Y5l\W62IH3hco5meg>? MYeyOVk6QDNzMh?=
MG63 NUDRN|FVSXCxcITvd4l{KEG|c3H5 NFq3V3cyOC9{MD:zNEDPxE1? NXPxR5dPOjRiaB?= NU\tUVd2e2mpbnnmbYNidnSueTDk[YNz\WG|ZXSgeIhmKGGyb4D0c5NqeyC{YYTlJI9nKE2JNkOgbY5lfWOnZDDifUBE\EOuMh?= NX;rNHFTOjV7OUizNVI>
HTSMCs MYLGeY5kfGmxbjDBd5NigQ>? NUXue4V3OC5zL{GvNVAh|ryP M2nzO|EhcA>? NHuzbIVqdmirYnn0[YQhS0:UTT2yMYlv\HWlZXSgTG8uOSCycn;0[YlvKGyndnXsd{BidmRibWLORUBmgHC{ZYPzbY9v NIr6WJozPTl{MUS2OC=>
MIA PaCa-2 NID1RmdHfW6ldHnvckBCe3OjeR?= NHzJSGczOMLizszN NIHab|UzPCCq MWXy[YR2[2WmIHzhZ5RifGViYXPjeY12dGG2aX;uJIlvKGOxbXLpcoF1cW:wIIfpeIgh[m:2aDCyMWRIKGGwZDDEMYFtdG:|ZdMg MlvMNlU5QDh2OEm=
MIA PaCa-2 NX\Ie|IxTnWwY4Tpc44hSXO|YYm= Mn;DNlDDqM7:TR?= NXnyUWMzOjRiaB?= Mmi5doV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y|rFicILveIVqdiCjY3P1cZVt[XSrb36= NWTGdWpWOjV6OEi0PFk>
BxPC-3 MkCwSpVv[3Srb36gRZN{[Xl? MXeyNOKh|ryP NHLLRnkzPCCq Mn\DdoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y|rFicILveIVqdiCjY3P1cZVt[XSrb36= NULGZpE4OjV6OEi0PFk>
AsPC-1 MXfGeY5kfGmxbjDBd5NigQ>? MYmyNOKh|ryP NInYZ4wzPCCq NEXRfHpz\XO3bITzJIlvKGFibX;k[ZN1KGmwaHnibZRqd25ib3[gTGlHNTIQsTDwdo91\WmwIHHjZ5VufWyjdHnvci=> MWeyOVg5QDR6OR?=
MIA PaCa-2 NF22OFNHfW6ldHnvckBCe3OjeR?= MUCyNOKh|ryP MWmyOEBp MVPlcohidmOnczDjcIVifmGpZTDv[kBRSVKSIIfo[Y4h[2:vYnnu[YQhf2m2aDDncJVkd3OnIHHuZYxw\3N? NVLkSI9oOjV6OEi0PFk>
MIA PaCa-2 NX21U|JuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqyNOKh|ryP NY\iWmpbOiCq M361TpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? MY[yOVg5QDR6OR?=
BxPC-3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[3NlDDqM7:TR?= NUPYWINEOiCq Mmnld4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm NVvtRpo{OjV6OEi0PFk>
AsPC-1 M2nqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fr[FIxyqEQvF2= NIS5RVgzKGh? MYHz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MV2yOVg5QDR6OR?=
HEY Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL1cWNYOjEEoN88US=> M4HwV|IhcA>? MVPz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> NVz6[nB5OjV6OEi0PFk>
OVCAR-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrySmMzOMLizszN Mn;oNkBp NEDMeXB{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? NFjPZlkzPTh6OES4PS=>
SK-OV-3 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D4[FIxyqEQvF2= NXT2PXpvOiCq M1r6[pNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NV3lZZZyOjV6OEi0PFk>
MH7A  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jo[VI1KGh? M1uyfJJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5? NYLWfGZjOjV6NkK5OlY>
MH7A  NImxO4tCeG:ydH;zbZMhSXO|YYm= M1fQdVI2KM7:TR?= MlvoNlQhcA>? MWfy[ZZmenOnczDj[YxtKGO7Y3zlJIFzemW|dDDpcoR2[2WmIHL5JHhCViCjbnSgZ4F2e2WmIHHwc5B1d3OrczDv[kBk\WyuczD2bYEh[WO2aY\heIlwdiCxZjDKUms> Mn3kNlU5PjJ7Nk[=
SCC25 M1TaS2Z2dmO2aX;uJGF{e2G7 M3zlVFIxKM7:TR?= M4jOUlI1KGh? MX\pcoNz\WG|ZYOgZZV1d3CqYXf5JIxmfmWu MVuyOVg{PDRyMB?=
HaCaT  MVvGeY5kfGmxbjDBd5NigQ>? MnvQOUDDvU1? NFjs[2ozPCCq MXnpcohq[mm2czDJSm4u|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=> NYrDTYRMOjV6M{SzOVM>
HaCaT  MkjFSpVv[3Srb36gRZN{[Xl? M3XYUVUhyrWP MoXHNlQhcA>? NEnmWHlqdmirYnn0d{BKTk5vzsGtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? NHS1emwzPTh|NEO1Ny=>
HPAEpiCs  NI\kbGlHfW6ldHnvckBCe3OjeR?= MV6xM|MwOTBizszN M1XsRlEhcA>? NX\FdWVqemWmdXPld{BUOVBvaX7keYNm\CCLQ1HNMVEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= MYeyOVc{PDlyMB?=
HPAEpiCs MYfGeY5kfGmxbjDBd5NigQ>? MlfaNU8{NzFyIN88US=> Mn\DNUBp M2O1[IlvcGmkaYTzJHMyWC2|dHnteYxifGWmIFHreEBxcG:|cHjvdplt[XSrb36gJOKh MkSzNlU4OzR7MEC=
HPAEpiCs NYS4SZBRTnWwY4Tpc44hSXO|YYm= MV2xM|MwOTBizszN MoDlNUBp NV\BPJpFcW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44> MXOyOVc{PDlyMB?=
K562 M{PrSmZ2dmO2aX;uJGF{e2G7 M{nrUFExyqEQvF2= NGfYR2MyyqCq MojXSG1UVw>? MonCbY5pcWKrdIOgdZVqdmGlcnnu[U1qdmS3Y3XkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= MmLCNlU3QDRyNEO=
PANC-1 M1j1N2Z2dmO2aX;uJGF{e2G7 MnjENVAh|ryP MoLTNUBp Mljl[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB? MWKyOVY{OjJ{Mh?=
BxPC-3 NHXp[2ZHfW6ldHnvckBCe3OjeR?= NH7IVVUyOCEQvF2= MlrFNUBp NVn6SJlQ\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC= M1nGUVI2PjN{MkKy
K562  MnfESpVv[3Srb36gRZN{[Xl? MV6wMlI2NTFizszN MYSyOEBp NHyxdHF{fXCycnXzd4V{KHKnc4\ldoF1em:uLXnu[JVk\WRiSELBXEBxcG:|cHjvdplt[XSrb36= MorpNlU3OTl|OUK=
THP-1 MXrGeY5kfGmxbjDBd5NigQ>? MV61JOK2VQ>? NVvlZ5Z7OiCq MWXzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNic3XjdoV1cW:wIH;mJGlNNTIQsTDpcoR2[2WmIHL5JFI4V0iFaH;sJJBtfXNiRmPMMVHDqA>? MmXYNlU2QTh4NkG=
WB MnmxSpVv[3Srb36gRZN{[Xl? MViyNQKBkc7:TdMg NVLNPIpJOzEkgJntbY4> NGGyUGFl\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u NWq4c2ltOjV3M{C2PFI>
RAW 264.7 MoSzSpVv[3Srb36gRZN{[Xl? NI\Nd5gyOMLizszN Mn\tN|DjiImvaX6= NWTXS3F6cW6mdXPld{BkcGG{YXP0[ZJqe3SrYzD2ZYN2d2yjdHnvckBw\iCRQ4RCpC=> M1np[|I2PDZzM{m5
RAW 264.7 MVnGeY5kfGmxbjDBd5NigQ>? M3zHSVExyqEQvF2= M3:5SlMx6oDLbXnu MnWzZZR1\W63YYTld{B1cGViZX\m[YN1eyCxZjDPVGchd25ib4P0[Y9kdGG|dDDy[ZRz[WO2aX;u MnTLNlU1PjF|OUm=
HaCaT  MVXGeY5kfGmxbjDBd5NigQ>? M1LzZlQxyqEQvF2= M4\id|MuOjRiaB?= NIriN3NFVVOR NYfPN5NwemWmdXPld{B1cGViYXPjeY12dGG2aX;uJI9nKFqRLUG= MU[yOVQ{PTR6NR?=
H9c2 NG\CboRHfW6ldHnvckBCe3OjeR?= MUC1NOKh|ryPwrC= NYfJNml4OTJiaB?= NYDrfoNFemWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O= MXmyOVI1PThzOB?=
HSCs NH\4U4tCeG:ydH;zbZMhSXO|YYm= NEDxRnczPSEQvF2= NEPje2ozPMLiaB?= MoHJd4lodmmoaXPhcpRtgSCjdITlcpVifGW|IGTHMYlv\HWlZXSgZYN1cX[jdHXkJGhUS3NiYYDvdJRwe2m| NWrKOJQxOjR7NkG5OVA>
THP-1 NV71PFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXG3NkBp M4HBdGROW09? NUjEUmZsUUN3ME20MlfPxE1? M1X3RlI1QDF3MEi3
MDDCs M4fBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrhXlR2PzJiaB?= MWrEUXNQ MU\JR|UxOi55zszN NIXsSmIzPDhzNUC4Oy=>
MDDCs M322d2Z2dmO2aX;uJGF{e2G7 NXL1WJU3OC1zNTFOwG0> NE\0Tmw1QCCq M1zLZWROW09? NEDr[oN{fXCycnXzd4V{KEmITj5OtUBidmRiSWCtNVAheHKxZIXjeIlwdsLi NXzVUlhSOjR6MUWwPFc>
MDDCs MVTGeY5kfGmxbjDBd5NigQ>? Mn2yNE0yPSEQvF2= NV7FPWxbPDhiaB?= NH\rbZNFVVOR NWrYSlFtcW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v NULuVpdCOjR6MUWwPFc>
MDDCs M3rVfGZ2dmO2aX;uJGF{e2G7 M3vTOlExKM7:TR?= Mn7EN{42KGh? MnrOSG1UVw>? MXTicI9kc3NiRVLPWkBIWCxiYoX0JI5wfCCYU2[gS{Bu\WSrYYTl[EBmdnS{eTDpcpRwKGi3bXHuJG1FTEO| M3TQUFI1QDF3MEi3
macrophages MmnxSpVv[3Srb36gRZN{[Xl? MXix5qCK|ryP NETtWnQ1NjYkgJno MX7jc41xdGW2ZXz5JIlvcGmkaYTzJG1VNUmLST3pcoR2[2WmIHHjeIl3[XSrb36gc4YhVkZvzsrC MVyyOFgxQDZ|Mx?=
PDL  MYHGeY5kfGmxbjDBd5NigQ>? NGnjeY8zOMLizszNxsA> Mnz2N|AhdWmw M{DPOGROW09? M2XuTJNq\26rZnnjZY51dHliaX7obYJqfHNidHjlJJRmdnOrbHWg[o9z[2VvbXXkbYF1\WRiQl3QMVIh\XiycnXzd4lwdg>? MVuyOFU3OTB6MR?=
AGS M2WyOWZ2dmO2aX;uJGF{e2G7 M{HCelUh|ryP M17EcVMxKG2rbh?= NUXoc5dqe3WycILld5Nme8LiMT3pcoR2[2WmIHPhd5Bie2VvODDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? MmfJNlQ2PDd6N{i=
H520 NHLnR2VHfW6ldHnvckBCe3OjeR?= NGjDZ5IyOMLiwsXN NF3Zc4wyKGh? NIrXblZFVVOR NYXWSZhR\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> MV[yOFU{ODR5NR?=
H1703 M1zPVWZ2dmO2aX;uJGF{e2G7 NH30cYkyOMLiwsXN NYHDVWxFOSCq MYnEUXNQ NV:yZ4NG\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> MUeyOFU{ODR5NR?=
H520 MXfGeY5kfGmxbjDBd5NigQ>? NF23bWkyOMLiwsXN Mnf1NVIhcA>? MVnEUXNQ MmfabY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7 MoHmNlQ2OzB2N{W=
H1703 NGTBd3BHfW6ldHnvckBCe3OjeR?= NV3ySXd2OTEEoNM1US=> MnzLNVIhcA>? NEPrPYdFVVOR NHjoSIpqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm= NFrHe4EzPDV|MES3OS=>
H520 NVvyUHBjTnWwY4Tpc44hSXO|YYm= NH;2OZYyOMLiwsXN M2G1XFYhcA>? NF3T[4tFVVOR MUfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV? NYHsVVBGOjR3M{C0O|U>
H1703 MmLlSpVv[3Srb36gRZN{[Xl? MkPBNVDDqML3TR?= Mn;GOkBp NFTxPW1FVVOR MkLhd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n MUeyOFU{ODR5NR?=
MC3T3-E1 Moi3SpVv[3Srb36gRZN{[Xl? M{fpR|AvOy9|L{OwJO69VQ>? NGnFXHoyKGh? NUDpWGxD[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO|aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA> MVqyOFUxOjZ7Nh?=
MC3T3-E1 MVLGeY5kfGmxbjDBd5NigQ>? NHTiV3E{OCEQvF2= NVTDXVlyOSCq MUDheJRmdnWjdHXzJHRPTi4QsT3zeIlufWyjdHXkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?= MnHzNlQ2ODJ4OU[=
HUVECs  M3zCbmZ2dmO2aX;uJGF{e2G7 NGTqT|YyOMLiwsXN NIDG[IcyKGh? MUPpcohq[mm2czDUUmYu|rFvaX7keYNm\CCFWFPMNUBxem:mdXP0bY9v MXeyOFQ5Pzl4NB?=
AGS  MVnGeY5kfGmxbjDBd5NigQ>? MVexNOKhyrWP NFfUV5g{OMLibXnu MnLybY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh? M1ryXlI1PDd7Nkix
MKN-45 MUTGeY5kfGmxbjDBd5NigQ>? NG\SNGwyOMLiwsXN MlfWN|DDqG2rbh?= NVGwXpZTcW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i= NHXybXMzPDR5OU[4NS=>
AGS  Ml7hSpVv[3Srb36gRZN{[Xl? MWSxNOKhyrWP MmK4N|DDqG2rbh?= M1zRfYF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v MnnWNlQ1Pzl4OEG=
MKN-45 NHXB[opHfW6ldHnvckBCe3OjeR?= Ml:0NVDDqML3TR?= NW\oZY55OzEEoH3pci=> NHXh[|NifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>? NEW0W2QzPDR5OU[4NS=>
AGS  M1LJPGZ2dmO2aX;uJGF{e2G7 MWSxNOKhyrWP NIHUe20{OMLibXnu NUTlRWw6e2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36= NHrpOoYzPDR5OU[4NS=>
MKN-45 NXfLUIY3TnWwY4Tpc44hSXO|YYm= NY\kUohPOTEEoNM1US=> M4LYVFMxyqCvaX6= MVTzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>? MUCyOFQ4QTZ6MR?=
DCs MoHsSpVv[3Srb36gRZN{[Xl? M17W[VIxyqEQvF2= NIHBdFMyyqCq MXTk[YNz\WG|ZYOgTWwuOTJicILv[JVkfGmxbh?= M4LINlI1PDN2NkO2
HUVEC  M4DBfmZ2dmO2aX;uJGF{e2G7 M{n5TlIxKM7:bdMg NYnuSZd6PSCq M{XrOGROW09? NVjydG83emWmdXPld{BkgXSxa3nu[UBmgHC{ZYPzbY9vKGyndnXsd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NFjLWHgzPDF6OUC2Ni=>
A 549 NVyxb4p2TnWwY4Tpc44hSXO|YYm= NULtOINUPTBizszN NXjLelZqOSCq NGf1PXBl\WO{ZXHz[ZMhfGinIHzleoVtKG:oIFnMMVjDqA>? NHT2[W0zPDF5OU[4PC=>
H520  MknrSpVv[3Srb36gRZN{[Xl? NYjWT2RPPS9zMDFOwG0> MXexJIg> NXf1fld4TE2VTx?= MX;k[YNz\WG|ZYOgUXNJOiCycn;0[YlvKGG|IIflcIwh[XNibWLORUBt\X[nbIOgbY4h\2WoaYTpcoljNWW6cH;z[YQh[2WubB?= MkXLNlQyOzh7MEO=
H1703  M3jFeWZ2dmO2aX;uJGF{e2G7 NH3BVmg2NzFyIN88US=> NXvTd5R4OSCq Mn73SG1UVw>? M13CPYRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs M3vDcVI1OTN6OUCz
H520  MYfGeY5kfGmxbjDBd5NigQ>? NVPtd3ZuOTEEoNM1US=> NIDydIQyOiCq NEnWc2JFVVOR Ml3F[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> MmrVNlQyOzh7MEO=
H1703  NY\DXlZVTnWwY4Tpc44hSXO|YYm= NUjmZXNvOTEEoNM1US=> MlPTNVIhcA>? MofiSG1UVw>? MnOw[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> M1fsRVI1OTN6OUCz
MCF-7  MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvHNVDDqM7:TR?= MV6yOOKhcA>? MmHPbY5pcWKrdIOgeIhmKEOUMUC4MYlv\HWlZXSgZ4VtdCCmZXH0bC=> NH;aVnAzPDF{OEi1Ny=>
HPAEpiCs NWPpfXRKTnWwY4Tpc44hSXO|YYm= MWmwMlEwOS9zMDFOwG0> NVPQ[lcyOSCq MUPpcohq[mm2czDUUmYu|rFvaX7keYNm\CClUFzBNuKheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9v NG[0fZkzPDB4OUG1PC=>
podocytes Ml\wSpVv[3Srb36gRZN{[Xl? MV[xNOKh|ryP MV2xJIg> MkfkbY5pcWKrdIOgWGdH|rJzLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOziPQWDLJIFv\CCHcnuxM|LDqA>? NHvOWm4zPDB|NkKxNi=>
MCF-7 MXLGeY5kfGmxbjDBd5NigQ>? NFvh[XEyOMLizszN M2DkRVEhcA>? NYT2eY1qTE2VTx?= MWfy[YR2[2W|IITo[UBYSS2rbnT1Z4VlKHCqb4PwbI9zgWyjdHXkJJA{QCCPQWDL Mn:yNlQxOTlyOUC=
MCF-7 M4X6NmZ2dmO2aX;uJGF{e2G7 NILq[YcyOMLizszN MYGyOEBp MlnnSG1UVw>? M4fpSYlv[3KnYYPld{B1cGViV1GtbY5lfWOnZDDhdI9xfG:|aYO= NUjxe2lHOjRyMUmwPVA>
HAPI M3HoRmZ2dmO2aX;uJGF{e2G7 NECyR3UyOC9{MD:0NOKh|ryP M4jYUVEhcA>? MlH0bY5pcWKrdIOgWGNFTC2rbnT1Z4VlKHB|OD;KUmshVUGSSzDwbI9{eGixconsZZRqd25? MWSyN|k3QTF{MB?=
HAPI M13kVmZ2dmO2aX;uJGF{e2G7 Ml;0NlDDqM7:TdMg MoDKNUBp MUXEUXNQ NXLiU2Jj[XS2ZX71ZZRmeyCWQ1TEMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCrTl;TJIFv\CCycn;keYN1cW:w MXGyN|k3QTF{MB?=
HepG2 MV7GeY5kfGmxbjDBd5NigQ>? MV2zOVAhdk1? NF7RO|MzPCCq MoGybY5pcWKrdIOgeIhmKGSnZ4XlcIlvNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDwN|hOSVCN MYeyN|k{OzF7OB?=
AGS  MUPGeY5kfGmxbjDBd5NigQ>? MUGxNOKh|ryP Mo\1N|AhdWmw NWfRSHlScW6qaXLpeJMh[2G|cHHz[U0{KGGldHn2ZZRqd25iYX7kJIlvcGmkaYTpc44hd2ZiRWLL M1nQdVI{QDVyOUm0
HepG2 M{LIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVriVWx2OC13MDFOwG0> NHi0bZE1QCCq NWPzT4pNcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1vpdFI{QDB5NUC4
BEL7404 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfW[4pEOC13MDFOwG0> NHGyXIk1QCCq Mlm2bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MlrMNlM5ODd3MEi=
HL7702 NWHZWWhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzTeW8xNTVyIN88US=> NHPJbHU1QCCq MVzpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX;wRW1COjN6MEe1NFg>
HepG2 NF3rd|NHfW6ldHnvckBCe3OjeR?= MUOwMVUxKM7:TR?= MXeyOEBp M4Pye4lvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26|dILlZY0heHKxdHXpcpMhVUGSS1HQT|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkXLNlM5ODd3MEi=
BEAS-2B MkD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNEDPxE1? NUXOW5FHOzBibXnu NFfzTJVz\X[ncoPld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDIR2k> MkLENlM4QDRyM{S=
BEAS-2B NXfs[m9rS3m2b4TvfIl1gSCDc4PhfS=> NGH6OFEyOCEQvF2= M3\xd|MxKG2rbh?= NYj1[3BxcW6qaXLpeIVlKHSqZTDpcoNz\WG|ZTDpckBNTEhiYX7kJGlNNThiZYjwdoV{e2mxbh?= NGTS[3QzOzd6NECzOC=>
BEAS-2B NE\0T|hHfW6ldHnvckBCe3OjeR?= NGrt[2syOCEQvF2= MUGzNEBucW5? M3;2N4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHPhd5Bie2VvMzygRoFlKGGwZDDmZZM> NWTUOVA3OjN5OESwN|Q>
H9c2  M{HXOGZ2dmO2aX;uJGF{e2G7 M4O0RVAvODFxMD6xM|Eh|ryP NYrqdHprOSCq MU\heJRmdnWjdHXzJHRPTi4QsT3pcoR2[2WmIF3NVE06KGW6cILld5Nqd25uIH3SUmEhdGW4ZXzzMEBidmRicILvcY91\XJiYXP0bZZqfHl? M4HMVVI{Pzd2MkWy
H9c2  MUHGeY5kfGmxbjDBd5NigQ>? MWGxJO69VQ>? NX[x[nNSOSCq NXfVe2JDemWmdXPld{BVVkZvzsGg[Ilz\WO2bImgd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= MX6yN|c4PDJ3Mh?=
U937 NXmxR5BlTnWwY4Tpc44hSXO|YYm= NFLXRXoyOMLizszNxsA> NFjZZ4UyKGh? MV;hZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6|Y4LpdJRqd26jbDDs[ZZmdHN? M1HjcVI{PzB5M{i3
U937 NVKzOVlpTnWwY4Tpc44hSXO|YYm= Mk\XNVDDqM7:TdMg Ml7jNUBp NVf6dZA1[WK{b3fheIV{KGOjZn\lbY5mNWmwZIXj[YQhVUuSLUGg[I94di2{ZXf1cIF1cW:wIHHu[EBRWDKDY98xJJVxNXKnZ4XsZZRqd25? MV6yN|cxPzN6Nx?=
U937 MmSySpVv[3Srb36gRZN{[Xl? MWOxNOKh|ryPwrC= MoDGNUBp MVLzeZBxemW|c3XzJIMuUnWwIHHu[EBEWkWEIIDoc5NxcG:{eXzheIlwdiCrbjDjZYZn\WmwZT30doVifGWmIHPlcIx{yqB? NEPQWXAzOzdyN{O4Oy=>
A549 NGe0WFBHfW6ldHnvckBCe3OjeR?= Ml2yNE4{NzNxM{Cg{txO NYHTTlFUOSCq M1XFeJNq\26rZnnjZY51dHliYYT0[Y52[XSnczDBWHDPu1NvbXXkbYF1\WRiQ1;YMVIheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2edMg M2nQN|I{PjhyNke0
A549 NUX4c5drTnWwY4Tpc44hSXO|YYm= NHXDdYYyOMLizszNxsA> NEjmUlUxNTNyIH3pci=> NXjTbHAxcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? MX6yN|Y5ODZ5NB?=
A549 MWnGeY5kfGmxbjDBd5NigQ>? NYfxblR3OTEEoN88UeKh NWOyUGNNOSCq NGHyUXpqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm= NFzjbpAzOzZ6ME[3OC=>
A549 M37IbGZ2dmO2aX;uJGF{e2G7 MlPLNVDDqM7:TdMg MXexJIg> MWDy[YR2[2W|IFHUVO6{Wy2|dHnteYxifGWmIHPQUGEzKHCqb4PwbI9zgWyjdHnvcuKh MYOyN|Y5ODZ5NB?=
A549 NHOxdHFHfW6ldHnvckBCe3OjeR?= MXyxNOKh|ryPwrC= NWK0VmNyOSCq MlHidoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC= MmrpNlM3QDB4N{S=
PC12 M1H1d2Z2dmO2aX;uJGF{e2G7 NWLXZXQzOTBxMkCvOFAh|ryP NI[2bYIyyqCq M{fsXIlvcGmkaYTzJGpPUyCjbnSgdFM5 MWqyN|U5PDN3Nx?=
HK-2 MoDJRZBweHSxc3nzJGF{e2G7 M3f3SVIxyqEQvF2= MlqyNlQhcA>? NFXCdplqdmirYnn0d{BGWktiYX7kJJA{QE2DUFu= MWiyN|U1OzF3MR?=
H9c2 MX;GeY5kfGmxbjDBd5NigQ>? Mn7hNeKh|ryP MonLNUBp Mn3ldoVlfWOnczDUUmYu|rFvaX7keYNm\CCPTWCtPUBuWk6DIHzleoVteyCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm= NYm3fItROjN|NUO2PVk>
H9c2 NFi2O3lHfW6ldHnvckBCe3OjeR?= MYCxxsDPxE1? MkHRNUBp Ml;qdoVlfWOnczDUUmYu|rFvZX7oZY5k\WRiQWCtNUBxem:vb4TldkBi[3Srdnn0fS=> MXKyN|M2OzZ7OR?=
H1650  M1rP[WZ2dmO2aX;uJGF{e2G7 NIn2eFIyOMLizszNxsA> NGntTYsyKGh? MYrEUXNQ M3f6VIRm[3KnYYPld{Bjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yx{KG:oIFXSR2MyKGmwIIDhZ4xqfGG6ZXyt[Zhxd3OnZNMgZ4VtdHN? MXqyN|IzQDZ7Nh?=
H1703 M3XpTWZ2dmO2aX;uJGF{e2G7 MVexNOKh|ryPwrC= NH7iUXUyKGh? M2nGZWROW09? MnXQ[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>? M3exT|I{OjJ6Nkm2
H1650  NHTLXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUixNOKh|ryPwrC= NUTEbIhSOSCq NG\Sd2ZFVVOR M1TtPIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NIXQO|MzOzJ{OE[5Oi=>
H1703 MmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKxNOKh|ryPwrC= MkfrNUBp MXLEUXNQ M2SyVYVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl? NWXZWm96OjN{Mki2PVY>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; 

PubMed: 26844273     


CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. 

pJNK1 / pJNK2 / JNK1 / JNK2 ; 

PubMed: 18222647     


A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described. 

26844273 18222647
Immunofluorescence
p-p38 / MMP9; 

PubMed: 24479681     


Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.

24479681
Growth inhibition assay
Cell viability ; 

PubMed: 26844273     


Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).

26844273
In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID